Any HIV therapy that reduces the risk of an immune cell being infected by a factor of at least 100,000 is enough to keep the virus in check, researchers reported.
The finding, from a detailed mathematical model of antiviral activity, suggests why some drugs and drug combinations do better than others, according to Robert Siliciano, MD, PhD, of Johns Hopkins University in Baltimore and colleagues.
And the model also demonstrated that the complexity and cost of HIV treatment might be reduced -- and access to treatment improved -- by choosing drugs based on their ability to inhibit infection, Siliciano and colleagues reported online in Nature Medicine.
Read the full story at: http://tinyurl.com/6weyevq
Source: MedPage Today